Hamza Suria Net Worth

The estimated Net Worth of Hamza Suria is at least $18 Milión dollars as of 20 December 2021. Mr. Suria owns over 36,645 units of AnaptysBio Inc stock worth over $3,746,722 and over the last 8 years he sold ANAB stock worth over $6,341,649. In addition, he makes $7,875,190 as President, Chief Executive Officer a Director at AnaptysBio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Suria ANAB stock SEC Form 4 insiders trading

Hamza has made over 16 trades of the AnaptysBio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 36,645 units of ANAB stock worth $41,042 on 20 December 2021.

The largest trade he's ever made was selling 65,585 units of AnaptysBio Inc stock on 10 December 2018 worth over $4,687,360. On average, Hamza trades about 15,394 units every 54 days since 2017. As of 20 December 2021 he still owns at least 105,245 units of AnaptysBio Inc stock.

You can see the complete history of Mr. Suria stock trades at the bottom of the page.

Hamza Suria biography

Hamza Suria serves as President, Chief Executive Officer, Director of the Company. From January 2009 to June 2011 Mr. Suria served as Vice President of Corporate Development. Before joining our company in December 2008, Mr. Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation and Astellas Pharma. Mr. Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.A. in biochemistry from Kalamazoo College. Our board of directors believes that Mr. Suria’s executive and industry experience, as well as his leadership in the development of our product pipeline across key therapeutic areas, provide him with the qualifications and skills to serve on our board of directors.

What is the salary of Hamza Suria?

As the President, Chief Executive Officer a Director of AnaptysBio Inc, the total compensation of Hamza Suria at AnaptysBio Inc is $7,875,190. There are no executives at AnaptysBio Inc getting paid more.

How old is Hamza Suria?

Hamza Suria is 43, he's been the President, Chief Executive Officer a Director of AnaptysBio Inc since 2011. There are 14 older and no younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.

What's Hamza Suria's mailing address?

Hamza's mailing address filed with the SEC is 10421 Pacific Center Ct, San Diego, CA 92121, USA.

Insiders trading at AnaptysBio Inc

Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 a James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.

What does AnaptysBio Inc do?

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Complete history of Mr. Suria stock trades at AnaptysBio Inc

AnaptysBio Inc executives and stock owners

AnaptysBio Inc executives and other stock owners filed with the SEC include:

• Hamza Suria,
  President, Chief Executive Officer, Director
• Eric Loumeau,
  Chief Operating Officer, General Counsel
• Hamza Suria,
  Pres, CEO & Director
• Dennis M. Mulroy,
  Chief Financial Officer
• Dr. Paul F. Lizzul,
  Chief Medical Officer
• James Topper,
  Independent Chairman of the Board
• Dennis Fenton,
  Independent Director
• Hollings Renton,
  Lead Independent Director
• J. Anthony Ware,
  Independent Director
• John Schmid,
  Independent Director
• Laura Hamill,
  Independent Director
• Paul Lizzul,
  Chief Medical Officer
• Dennis Mulroy,
  Chief Financial Officer
• Eric J. Loumeau,
  COO & Gen. Counsel
• David McKeon,
  VP & Controller
• Dr. Margaret Marino,
  Sr. VP of Project Management
• Beth Mueller,
  Sr. VP of HR
• Nicholas Lydon,
  Director
• Carol Giltner Gallagher,
  Director
• Matthew Moyle,
  Chief Scientific Officer
• James A Schoeneck,
  Director
• Dominic Piscitelli,
  Chief Financial Officer
• Marco Londei,
  Chief Medical Officer
• Healthcare Vii, L.P.Frazier...,
  
• Healthcare V, Lpfhm V, Lpfh...,
  
• Holdings A/S Novo,
  10% owner
• Ventures Vii L Pavalon Vent...,
  
• John A Orwin,
  
• Magda Marquet,
  
• Rita Jain,
  
• Capital, Llcnodelman Oleg E...,
  
• Capital, Llc Eco R1,
  10% owner
• Daniel Faga,
  CEO